Next-generation sequencing technology (NGS) revolutionized the sequencing of the human genome. According to authoritative sources, the cost of human genome sequencing is expected to drop to $1,000 in the next few years, and sequencing time is expected to be shortened to one to two days. The first generation of the Human Genome Project cost nearly $3 billion, compared to the new generation of sequencing technology, which has been greatly reduced in time and cost, providing greater convenience for clinical diagnosis.
IQ4I Research & Consultancy analyzes that the global next-generation sequencing market will reach $4.892 billion in 2020, with a compound annual growth rate of 20.7%. The IQ4I report covers the market benefits and key quantitative analysis that technology, platforms and end users/labs bring to the NGS market.
Due to the advantages of cost reduction and speed increase, the application of NGS technology has been greatly improved in clinical and individualized medicine . The transition from chips to NGS, the benefits of medical provision and research methods have brought tremendous growth to the NGS market. However, the outlook is not entirely bright, the standardization and accuracy of the NGS steps, the complexity of data interpretation and storage, the lack of skilled operators and the dependence of NGS on infrastructure investment are factors that constrain the development of the technology market. .
.jpg)
Instruments and consumables are an important part of NGS's global market, accounting for almost half of the market share in 2013. However, the fastest-growing segment is service, with a compound annual growth rate of over 20%.
The global NGS market can be divided into targeted re-sequencing, whole exome sequencing, RNA sequencing, whole genome sequencing, ChIP sequencing, de novo sequencing and methylation. Several parts of methyl sequencing. Among them, targeted re-sequencing has the largest share of the NGS market in 2013, and the fastest growth is whole exome sequencing, with an annual growth rate of more than 25%. Due to the large number of disease-related NGS trials and platforms, these two technologies have great development prospects.
According to the IQ4I report, the current academic researchers are the largest end users of NGS, accounting for about 60% of the market. However, by 2020, hospitals and clinical applications will exceed 40%. With the growing demand and application in the clinical field, the market share of NGS is expected to increase to 25% by 2020.
In terms of application types, the NGS market can be divided into cancer research, genetic screening, infectious disease research, drug and biomarker discovery, molecular epidemiology, agriculture, and other applications. Among them, tumor detection accounted for 35% of the market share of revenue and sample capacity, which is the most market share of NGS.
North America has the largest NGS market share in the world, with US$571 million in 2013, and the Asia Pacific region will be the fastest growing region in the future. The NGS market dominates Illumina, Thermo Fisher, Hoffmann-La Roche, Pacific Bioscience, Agilent Technologies, BGI, Qiagen, Biomatters and Genomatix Software, with Illumina being the leader, followed by Thermo Fisher Scientific and Hoffmann-La Roche. These companies account for more than 90% of the market.
Coverall Products,Durability Surgical Masks,Disposible Face Masks,Safety Protective Coveralls
Zhende Medical Co.,Ltd , https://www.zdmedicalproducts.com